Philip Morris International Inc. (PM) Earnings Call Transcript & Summary

July 22, 2026

New York Stock Exchange US Consumer Staples Tobacco earnings 70 min

What were the key takeaways from Philip Morris International Inc.'s July 22, 2026 earnings call?

In the second quarter of 2026, Philip Morris International Inc. (PM:US) reported strong financial results, with organic net revenue growth of 8% and adjusted diluted EPS of $2.20, reflecting a 15% increase in dollar terms. The company maintained its full-year guidance for organic net revenue growth of 5% to 7%, citing increased investments in the U.S. market as a strategic priority. Management highlighted robust performance in the smoke-free segment, particularly from IQOS and ZYN, while also noting a favorable pricing environment in combustibles, which contributed to overall profitability.

What topics did Philip Morris International Inc. cover?

  • Strong Smoke-Free Growth: The international smoke-free business delivered high single-digit volume growth and double-digit top line growth, with IQOS adjusted in-market sales volume increasing by 5%. Management stated, "Excluding these 2 markets, double-digit growth continued, reflecting the broad-based strength of our smoke-free business across markets."
  • Robust Financial Performance: Q2 adjusted operating income grew by 11% organically to reach $4.8 billion, driven by pricing, volume leverage, and a favorable smoke-free mix. Management noted, "This strong top line performance translated into robust profitability."
  • U.S. Market Investment Strategy: Management plans to accelerate investments in the U.S. market to support ZYN brand equity and portfolio expansion, highlighting a comprehensive marketing campaign. They stated, "We are really putting together now a portfolio that is really, I would say, nicely matching consumer demand and the evolution of the market."
  • Cautious Full-Year Guidance: Despite strong H1 performance, management maintained its full-year guidance, citing the need for increased investments. They explained, "The reason why today we are not revising the guidance is indeed the fact that we also are facing a very exciting moment in the U.S."
  • Combustible Performance: The combustible segment outperformed expectations with a 1.1% increase in Q2 shipments, driven by strong pricing and stable category share. Management remarked, "This combination of pricing power, brand leadership and disciplined execution translated into robust profitability."

What were Philip Morris International Inc.'s July 22, 2026 results?

  • Revenue: $11B (first time reaching over $11 billion in quarterly net revenues)
  • Organic Net Revenue Growth: +8%
  • Total Shipment Volume Growth: +2.5%
  • Gross Profit: +8.7% (organically)
  • Cigarette Shipments Growth: +1.1% (ahead of expectation)
  • ZYN Shipment Growth: +2% (to 2.9 billion pouches)

Overall, PMI's strong Q2 results and robust smoke-free growth signal a positive trajectory for the company. However, the decision to maintain guidance amidst increased investments raises questions about future profitability. Investors should monitor the execution of U.S. market strategies and the impact of regulatory changes on product performance.

Earnings Call Speaker Segments

James Bushnell

executive
#1

Hello, and thanks for being here. Earlier today, we put out a press release with full details about our results for the second quarter of 2026. You can find that press release on our site, pmi.com. A glossary of terms, which includes how we define Smoke-Free Products, plus adjustments, other calculations, and reconciliations to the most directly comparable U.S. GAAP measures for the non-GAAP financial measures mentioned in this presentation, can be found in Exhibit 99.2 of the company's Form 8-K filed today, and also on our Investor Relations website. With me today are Emmanuel Babeau and Massimo Andolina, who will take over from Emmanuel as Group CFO in August. Emmanuel, the floor is yours.

Emmanuel Babeau

executive
#2

James, appreciate that, and welcome to everybody on the call. I'm glad to report that Q2 was quite robust for us, with net revenue rising +8% on an organic basis and operating income climbing +11%, lifting adjusted diluted EPS by +14% in currency-neutral terms to $2.20, and by +15% as reported in dollars. That outcome exceeded our own forecast and contributed to a very solid first half despite the tough year-over-year comparison we ran into during Q1. As before, our second-quarter figures reflected the strong, expected results from our international Smoke-Free Products unit, which delivered high single-digit growth in volume, double-digit gains on the top line, and a notable improvement in gross margin. For IQOS, adjusted in-market sales volume was up 5%. That figure reflects transitory headwinds we had anticipated, tied to Japan's April excise hike and Poland's ban on characterizing flavors. Away from those two countries, growth stayed in the double digits, which mirrors the broad-based strength of our Smoke-Free Products business across geographies. Momentum keeps building in our multi-category commercial approach, backed by ZYN and VEEV. On combustibles, performance exceeded our expectations in what was a particularly strong quarter, with volumes rising, very good pricing, a stable category share, and gross profit growth. We don't expect to match that volume of shipments at the same scale for the rest of the year. Still, outcomes such as these demonstrate the strength of our portfolio, since we draw on our cigarette leadership to help legal-age smokers move toward better options. In the U.S., net revenues, gross profit, and operating company income all improved notably on a sequential basis versus a difficult Q1. The U.S. nicotine pouch category continued to expand, and ZYN offtake volumes were roughly flat to modestly higher compared with a year earlier, which reflects the uneven competitive conditions we've talked about over recent quarters. On this call, we reported that ZYN volume climbed 2%, reaching 2.9 billion cans, even though we had faced a favorable inventory comparison a year earlier. That performance largely tracked consumer offtake and the first shipments of new versions, ZYN Ultra among them. This opening step in widening the portfolio has us enthusiastic, and we have further efforts lined up over the next several months aimed at improving and broadening what we provide to American nicotine users of legal age. With a deep product pipeline behind us and regulations becoming clearer, we see this as the right time to step up our U.S. spending during the back half of the year — funding ZYN's brand equity and portfolio growth while getting ready for the eventual introduction of IQOS ILUMA. Taking everything into account, the strength we showed in the first six months gives us greater conviction that we can keep funding smoke-free growth opportunities on a steady basis while also producing yet another year of industry-leading increases on both the top and bottom lines. Moving to our second-quarter results, shipment volumes rose a solid +2.5%, supported by ongoing momentum in IQOS along with favorable combustible trends. Organic net revenues were up +7.6%, which comes to over 10% when measured in dollars, pushing quarterly net revenues past $11 billion for the very first time. That powerful top-line result fed through to strong profitability. Adjusted gross profit climbed +8.7% on an organic basis, or +11.5% in dollar terms, fueled by pricing, volume leverage, and a favorable smoke-free mix. On an adjusted basis, operating income rose almost 11% organically and 12% in dollar terms, landing at $4.8 billion, driven by the same fundamental business factors and ongoing investment in growth. Adjusted diluted earnings per share climbed a notable 15%, hitting $2.20. That figure includes a $0.03 tailwind from currency, which came in considerably better than we had forecast, even as the dollar stayed strong. The main reason was a beneficial effect from an unrealized transactional item tied to a deferred tax liability linked to a weaker Russian ruble. That currency benefit accounts for roughly one-third of the EPS beat versus our earlier guidance. The remaining two-thirds stems from a combination of SG&A phasing — certain commercial spending we'd anticipated for Q2 has been pushed into Q3 — along with the strong performance of our combustible segment, which I'll get into in a moment. If you combine Q2 and Q1, we delivered an excellent first half despite the difficult comps we faced in Q1. Overall shipment volumes climbed 0.4%, driven by smoke-free gains that exceeded combustible declines. Organic net revenues grew 5.3%, while adjusted operating income on an organic basis increased 6.1%, which translates to 11% in dollar terms, reaching $8.9 billion. Adjusted diluted EPS was up 9.4% on a currency-neutral basis and 15.6% in dollar terms, establishing a first-half record of $4.16. International made up 93% of our group net revenues in the first half, and it was clearly the driving force behind such a strong outcome. Within that, smoke-free products outside our home markets delivered another standout performance: organic net revenue rose 13.7% and gross profit climbed 16.9% in H1, which lifted gross margin by 190 basis points to 70%. That mostly reflects the ongoing momentum behind IQOS, plus additional gains from the rest of our smoke-free portfolio, VEEV in particular. Combustibles also performed strongly, surpassing the midterm trajectory we set of low single-digit organic top-line expansion and low to mid single-digit growth in gross profit. We had an excellent second quarter. Net revenue on an organic basis increased 6.4%, while gross profit grew 8%, driven by steady volumes and solid pricing. That performance allowed us to achieve 3.8% organic net revenue growth across the first half, even with an unfavorable geographic mix. First-half gross profit climbed 6.1%, and margin improved 150 basis points to 67.7%, supported by disciplined cost management. As a result, international net revenue for the first half was up 7.4% in total, gross profit increased 10.1%, and gross margin gained 160 basis points to reach 68.6%. Adjusted OCI, in turn, increased 11.7%, all of it organic. Turning to volumes: total shipments returned to growth during the second quarter, rising 2.5%, which delivered 0.4% growth for the first half. In the second quarter, smoke-free shipments increased 7.5%, and for the first half they were up 8.3%. IQOS HTUs were the main engine behind that, and we also saw sizable contributions from Taiwan, global travel retail, and Italy. E-vapor shipments climbed a striking 55% in Q2, and 72% across H1, with Romania, Greece, and Germany standing out as key drivers. During the quarter, oral smoke-free shipment volumes declined 1.2%, largely because of category contraction and a Snus inventory effect across the Nordics, although category share remained stable. Offsetting some of that, nicotine pouches continued to grow rapidly in international markets outside the Nordics, and ZYN shipment volumes in the U.S. got back to growth. Cigarette shipments in Q2 were up 1.1%, which came in above our expectations. That comes from solid category share results, some timing or comparison effects, and improved industry conditions in a number of large markets, chiefly those where smoke-free products are prohibited or minimal. Worth flagging are Indonesia, Turkey, Egypt, plus comparatively steady trends in India and Mexico; yet because industry volumes are falling by low to mid single digits in more developed smoke-free markets, where cigarette average unit economics are better, this created an adverse mix effect on net revenue. Across H1 as a whole, cigarette volumes were down 1.9%. With our Q2 results and the newest industry trends in mind, we now foresee a gentler full-year reduction in our cigarette volumes of roughly 2%-3%, compared with 3% before, still in line with the category's structural evolution. All told, we now anticipate total shipment volume to be about flat to marginally up for the full year, as high single-digit growth in smoke-free products largely counterbalances the cigarette decline. Now to our H1 top-line growth drivers.

Emmanuel Babeau

executive
#3

When it came to driving growth, price was the biggest factor, contributing +5.9 points. That came from robust combustible pricing at +9.2%, plus smoke-free pricing in the low single digits, which included roughly +3% from IQOS. International smoke-free expansion also improved our mix, adding another +2 points, since smoke-free products keep gaining weight and that lifts our revenue profile. Partly working against these gains was the U.S., which subtracted one point, largely because of the Q1 comparison, along with international combustible geographic mix and other items, which cut growth by two points. All told, organic net revenue growth for H1 came to +5.3%, and currency gave us a +4.5 point tailwind, so reported net revenue growth landed at +9.8%. Once again, the makeup of our growth shows how consistent and sustainable our model is, with volumes stable to rising, pricing power that lasts, and superior smoke-free economics remaining the main engines of our performance. Turning to H1 adjusted operating income margin, it rose +40 basis points organically, or +60 basis points in dollar terms, to just under 42%. Gross margin expansion stayed a major factor, adding +70 basis points, helped by strong pricing, a favorable smoke-free mix, scale benefits, and manufacturing productivity. Although SG&A costs came in below expectations in Q2 because of phasing, higher year-on-year spending on commercial initiatives, innovation, and scale still trimmed H1 margin by 30 basis points. We now anticipate greater SG&A costs in the second half than we previously expected, since we made the strategic choice to increase our U.S. growth investment. Even as we put money into the top line, we still generated more than $300 million in gross cost savings across COGS and SG&A during H1, which keeps us solidly on course for our $2 billion target covering the 2024 to 2026 period, with a cumulative total exceeding $1.8 billion so far. This margin result highlights how strong our model is, as we keep investing behind our smoke-free transformation while also growing profitability. As our full-year forecast implies, we expect to deliver organic operating income margin expansion for the entire year. Now turning to IQOS, the key engine behind both our smoke-free growth and our overall PMI growth trajectory; despite temporary headwinds in Japan and the final EU flavor ban market implementation, we keep producing strong underlying growth. Adjusted in-market sales volume rose +8% in the first half, and even with those dynamics, that reflects broad-based global momentum. The slowdown in Q2 growth to +5.1% mainly mirrors expected volatility in Japan, as Q1 pantry loading unwound and consumers adapted to the excise-driven price increase on April 1st. If you set aside Japan and Poland, Q2 growth was robust at +10.2%, or above +11% for H1, in line with recent history. Solid Q2 results in more mature IQOS markets like Italy, Greece, and Romania were paired with ongoing momentum in newer markets such as Saudi Arabia, the Philippines, Mexico, and Taiwan, which continues its impressive trajectory, with offtake volume rising double-digit sequentially as we steadily broaden distribution. Global travel retail likewise posted adjusted IMS growth in the double digits. At the same time, we're pushing hard on commercial execution and continuous innovation throughout our device and consumable lineup — the Remix Special Edition featured on this slide is just one illustration. We're also broadening our alternative heating technology, BONDS by IQOS, introduced during the quarter in Poland, the Czech Republic, and Morocco, where early results look encouraging. IQOS's underlying strengths haven't changed. Formidable brand equity, a deep bond with consumers, and unmatched commercial reach spanning a wide, diversified geographic base keep working in our favor, and within the rapidly expanding heat-not-burn category we hold roughly 76% of global share in H1. Kantar's ranking of IQOS among the 100 most valuable global brands for the first time offered further proof of that. Turning to IQOS offtake share, we keep making striking headway in major cities around the world — a key early signal of wider national uptake. During Q2, we posted additional solid share gains throughout mature IQOS markets, among them Greece, Italy, Romania, and the U.K., together with global travel retail. Momentum is also looking very good in newer IQOS markets, particularly Mexico, Indonesia, and Taiwan, where tobacco share stands near 8% amid a seasonally larger overall cigarette market. Such outcomes mirror our robust commercial execution, plus IQOS's growing footprint and scale in more mature markets, paired with superb early uptake in newer ones, which strengthens our conviction in the long-term growth path. On e-vapor, VEEV keeps producing outstanding results, with H1 shipment growth of +72% and solid improvement on financial measures, profitability among them. That mirrors vigorous expansion across major open markets, cementing VEEV's leadership. VEEV now stands as the unambiguous number one brand in Europe, across both closed pod and pods plus disposables combined, and the estimated top closed pod brand in global travel retail wherever VEEV is sold — all ahead of long-entrenched competitors. The category's structural shift backs this up, since closed pods have become the dominant format internationally, leaving aside illicit and open systems. Strong consumer retention and brand loyalty underpin our results, aided by responsible innovation and ongoing portfolio upgrades. Among these is the gradual rollout of VEEV One Plus, our newest technology, delivering a heightened consumer experience via a compact premium design, swap and store functionality that fits two pods in a single device, and a replaceable battery that lasts longer. As for ZYN, international shipment volume rose +6% in the first half, or +32% once the Nordics are excluded. ZYN kept winning share in this small yet rapidly growing category, reaching over 17% of the international segment in Q2, excluding the Nordics. We're witnessing encouraging headway across a wide range of geographies, backed by portfolio expansion and consumer uptake as awareness and availability rise. That covers markets including the U.K., Pakistan, Poland, Greece, and the Philippines, with additional footprint and portfolio expansion slated for the second half. Turning to Europe now, we’re in every market there with smoke-free products after IQOS launched in Malta during Q2, and Malta just put a new regulatory framework in place for smoke-free products. Our multi-category portfolio produced strong growth, with combined IMS rising 8% in H1, as ZYN and VEEV get stronger and complement IQOS, helping growth, consumer acquisition, and long-term value creation. IQOS is still the main engine behind our performance, with adjusted IMS volume increasing 5.1% in Q2 and 5.4% across the first half. We managed that even with continuing disruption in Ukraine and the effect of recent flavor bans in markets including Poland and Hungary. If you set aside markets where the ban took effect during the prior 12 months, underlying IQOS adjusted IMS growth stayed solid at roughly 8% for both Q2 and H1, which shows momentum throughout the region. That covers excellent growth across a wide range of markets, such as Italy, Germany, Romania, Bulgaria, Greece, and Spain, backed by our innovation and commercial initiatives, including the broader rollout of DELIA, new variants of TEREA and LEVIA, special edition devices and consumables, and collaboration with partners who share our commitment to innovation, reinvention, and transformation.

Emmanuel Babeau

executive
#4

VEEV has achieved worldwide success, yet nowhere does it matter more than in Europe, where e-vapor usage runs deep. During the first half, shipments climbed 81%, with standout performances in Romania, Greece, and Germany. Much like the overall international trajectory, ZYN posted vigorous growth of roughly 33% outside the Nordics as the category kept building momentum. In Japan, IQOS fundamentals stay solid even though pricing and timing effects were anticipated to create swings. First-half results landed right where we expected, with adjusted IMS up 3.4%. After an extraordinarily robust first quarter, adjusted IMS for Q2 fell 3.4%, which mirrors consumers unwinding the stockpiling they did before the April 1st price hike tied to excise. Strip out that effect, and underlying growth came to about 1%. That does mark a slowdown versus recent quarters, but the early consumer response to the higher price matched what we had anticipated. The April excise adjustment forced the steepest HTU price hike Japan has seen to date so the tax could be passed along, whereas cigarettes saw no excise movement. Even after putting through the market's biggest increase, IQOS adjusted category share stayed in the high 60s, and adjusted IMS bounced back well across the quarter to roughly equal Q1 monthly volume once pantry loading is excluded — further proof of IQOS durability. Even with all this, IQOS-adjusted HTU share in Q2 held steady at 31.8%, or rose 0.9 percentage point when pantry loading is excluded, lifted by our tier portfolio, where SENTIA proved key in drawing in more price-conscious TEREA users. Crucially, underlying demand stayed vigorous. Heat-not-burn kept accounting for over half of all nicotine offtake, and we anticipate that share will keep expanding as time goes on. The largest step is now behind us, but we still foresee added category swings in H2, particularly tied to the October excise change, and we would expect comparable consumer patterns, such as pantry loading followed by normalization. For the full year, we remain focused on growing IQOS adjusted IMS volume. Turning to the U.S., we posted sequential gains of 38% in net revenue and 46% in adjusted gross profit against a difficult Q1. That mostly mirrors the 25% sequential rise in ZYN shipments plus lower sales promotion ahead of new product rollouts. Year on year, segment net revenue dropped just under 1%, dragged by cigars and an unfavorable phasing dynamic in the wellness business, while ZYN net revenues were essentially unchanged. Gross profit took a hit from elevated manufacturing costs, chiefly from ramping new ZYN capacity in Colorado, where full-scale commercial production started this month, underscoring our ongoing investment to fuel future growth. ZYN shipments resumed growing, up 2% year on year to 2.9 billion pouches, even against an inventory restocking tailwind of roughly 150 million pouches a year earlier; that expansion roughly tracks stable-to-slightly-growing offtake volume and covers some initial June shipments of new variants, among them the ZYN Ultra range, which holds 20 pouches per can. Turning to the back half of the year, we anticipate that ZYN's momentum will be strengthened through our broadening lineup and stepped-up commercial efforts, which I'll address in a moment. That said, it's worth flagging that the volume comparison for Q3 is going to face a headwind from the one-time promotional push that took place in September of 2023, which represented roughly 250 million pouches. The key point is that ZYN continues to hold a distinct premium leadership position within the nicotine pouch segment, capturing a retail value share of approximately 57%. As we've noted in earlier disclosures, our recent share performance within the category has been pressured both by competitive white spaces in the fast-growing higher strength segment, including moist product and certain flavor segments, and by an elevated price premium; now that regulatory clarity is improving and our operational readiness is in place, we've taken an initial step to tackle this through additional variants. That began with the rollout of ZYN Ultra in nine and 11 milligram moist variants, priced lower on a per-pouch basis than the ZYN flagship range of dry pouches, which brings down the price premium versus our nearest competitor while preserving a distinct premium position, alongside a targeted addition to our flagship flavor range; these new variants are quickly gaining distribution, and though it's still early, we're encouraged by promising initial offtake trends and favorable consumer response. As a related note, I'd point out that while scanner data usually give a solid directional read on volume trend, they don't always fully reflect the effective consumer price. We intend to extend further in the months ahead, among other things introducing 1.5 milligram and eight milligram dry formats during Q3. Taken together, these launches will widen our offering with a broader array of strengths and taste profiles, letting us better serve the full spectrum of legal-age consumer preferences and further bolster our competitive positioning across segments; given such an exciting lineup of new products to round out the existing portfolio, we intend to speed up our U.S. investment during the second half. That encompasses a wide-ranging commercial program spanning marketing, distribution, and in-store execution, with a rollout of our major new brand campaign, When it Clicks, beginning this month to drive brand engagement and consumer relevance; we're also putting commercial initiatives in place to fine-tune ZYN's premium positioning and improve how consumers perceive its value; on top of that, our U.S. investment covers preparation for the eventual launch of IQOS ILUMA, subject to FDA action; we likewise believe ZYN sits in a strong position from a regulatory perspective, particularly after the modified risk tobacco product authorization of 20 SKUs, which makes it the sole nicotine pouch product holding that designation and permits us to market the claim, "Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis." This further cements its differentiated and sustainable positioning, underpinning consumer trust and long-term growth potential. All told, we stay confident in ZYN's long-term trajectory and the U.S. Turning to the nicotine pouch segment, which is backed by robust demand from consumers of legal age along with the money we're putting into responsibly bringing to market a substantially upgraded lineup of products aimed at securing long-term leadership. Last, on to combustibles, where our business turned in a notably strong second quarter. Beyond the positive volume trend I mentioned before, the result came from a pricing variance of +9.2% across the first half, or nearly +10% in Q2, with meaningful contributions from markets such as Turkey, Indonesia, the Philippines, and Mexico. Though we anticipate a degree of moderation in H2 stemming from timing factors and annualization, we now project a pricing variance above 7% for the entire year. That said, we expect this extra gain to be mostly offset by a less favorable geographic mix, since volumes tilt more toward markets generating lower per-unit revenues. Even with pricing that strong, our portfolio held its international category share at 25.3% in Q2, as Marlboro once more showed the power of its premium brand equity, equaling its record high of 11%. This blend of pricing power, brand leadership, and disciplined execution produced robust profitability, with international combustible gross profit rising +6.1% on an organic basis and by an impressive +8% in Q2. Our combustible business keeps proving the strength of its model, generating solid top and bottom-line growth while underpinning the continued expansion and rising profitability of our smoke-free portfolio.

Emmanuel Babeau

executive
#5

That leads me into what we expect for the whole year. Our smoke-free operations outside the U.S. are expanding quite rapidly, in line with what we anticipated, and the combustible side is doing better than we had previously assumed, so we have extra room to put money to work while still keeping up a growth performance that leads the industry. PMI's achievements rest on spending in the near term to fuel expansion over the long haul — exactly what we did with IQOS and, going back many decades, with Marlboro. What has defined us across the past 15 years is that alongside our investments, we keep producing robust growth and strong cash flow. For 2026, our targets remain unchanged: organic net revenue growth of +5% to +7%, organic operating income growth of +7% to +9%, and currency neutral adjusted diluted EPS growth of +7.5% to +9.5%. Measured in dollars, we now project a currency tailwind of roughly $0.15 at prevailing rates, which works out to an adjusted diluted EPS range of $8.26 to $8.41 — a rise of 9.5% to +11.5%. Assuming volumes are broadly flat to up slightly, we are likewise pursuing a sixth straight year of total volume growth. For the second half, that points to another strong top line plus faster organic operating income growth. On top of further solid international progress, we should see momentum in the U.S., even though international HTU shipments will be fairly evenly spread across the four quarters, with shipments roughly matching adjusted IMS for the full year. At the EPS level, we likewise anticipate solid improvement, while flagging a tough H2 comparison on net finance cost and the effective tax rate. Turning to Q3 in particular, we anticipate HTU shipment volume of approximately 41 billion units, set against a strong Q3 2025 when HTU shipment rose by 15.5%. So we look for mid-single-digit growth in international smoke-free organic net revenue and gross profit. Across PMI as a whole, we project mid-single-digit Q3 organic top-line growth alongside modest organic margin expansion. We are targeting adjusted diluted EPS of $2.20 to $2.25, which includes an unfavorable currency impact of $0.08 at prevailing exchange rates. That figure also captures the difficult tax rate comparison versus Q3 last year. We still anticipate operating cash flow generation of approximately $13.5 billion, which gives us added flexibility to fund both investment and continued attractive shareholder return. With that, let me wrap up today's presentation with a few key takeaways. We turned in an excellent first half, which highlights the quality of our business model and keeps us squarely on track for yet another year of strong performance. Our results show the potent blend of smoke-free growth and strong combustible execution, as the profitability of our smoke-free portfolio keeps getting better while IQOS, ZYN, and VEEV build scale and generate synergies across markets. That performance, along with effective cost management, gives us the flexibility to reinvest behind our smoke-free future while sustaining best-in-class growth; we also stay a highly cash-generative business with an unwavering commitment to our progressive dividend policy and to returning value to shareholders. As we look forward, we face the rest of 2026 with confidence, well-positioned to deliver superior and sustainable growth. Switching to something more personal: since this marks the final time I'll join an earnings call in my role as Group CFO at PMI, I want to express my gratitude to those of you who hold shares and to the analysts covering us — for the backing, the involvement, and the tough questions you've raised across 6 years defined by solid results and returns to shareholders. Looking at where the company stands right now, my confidence is strong that PMI will keep standing out as a top performer in CPG in the years ahead, and I'm handing things over to a very capable successor, Massimo Andolina, who makes the move out of his present position in August.

Massimo Andolina

executive
#6

Thanks, Emmanuel. Hello, everyone — good morning, good afternoon. Emmanuel, to start, I want to recognize how much you've done for our company's results across recent years, and the strong partnership you and I have shared, both during my earlier positions and throughout this transition. Emmanuel, I know full well that the shoes you're leaving behind are large ones to fill, and over the months ahead I'll keep relying on your help to do that well. Thank you. It's a real privilege to step into the Group CFO role at Philip Morris International, and to keep up our unwavering drive to produce outstanding returns for shareholders across the long term. Our business model is highly resilient, founded on putting money into sustainable smoke-free expansion, and we have a capable, gifted organization with a superb history of delivering value to shareholders. I'm eager to connect with our investors, our analysts, and every other stakeholder in the months to come and past that.

James Bushnell

executive
#7

Appreciate that, Massimo, and thanks as well, Emmanuel. At this point, the team would be glad to take whatever questions you have.

Bonnie Herzog

analyst
#8

OK, thanks. Emmanuel, working alongside you has been a real pleasure, and I truly hope everything goes wonderfully for you going forward.

Emmanuel Babeau

executive
#9

Thanks, Bonnie.

Bonnie Herzog

analyst
#10

Yes, thanks for having me. My initial question concerns your guidance. Even though you've posted two quarters that beat expectations and showed real momentum, you still kept your full-year underlying growth outlook unchanged. I simply wanted to confirm that this mostly stems from your strategic choice to ramp up investments in the U.S. during the second half, or whether there's another factor we ought to keep in mind. Your guidance does still suggest income growth will be somewhat quicker in 2H than in 1H. I was hoping to grasp how much room you have to maneuver with this higher spending — could you perhaps share a bit more detail about these planned investments? For example, should we expect a significant increase in promotional spending supporting ZYN?

Emmanuel Babeau

executive
#11

Thanks, Bonnie. H1, as you've observed, was excellent. The reality is that following a superb H1, with genuinely encouraging developments in Q2 across the globe and particularly the confirmation of a robust smoke-free business, CC, which is performing above expectations. The explanation we aren't updating the guidance today is precisely because we're also encountering a highly thrilling period in the U.S. We have a convergence of favorable circumstances that is, naturally, wonderful. We have, as we've been describing, a far wider range of variants. We're introducing additional flavor to our dry lineup, and you've witnessed that. We mention peach, dragonberry, and black cherry; we're now launching ZYN Ultra. With nine and 11, we're declaring that we're introducing 1.5 and eight milligrams; we're truly assembling a portfolio that, I'd say, aligns nicely with consumer demand and how the market is evolving; beyond that, we have our fresh marketing campaign, When it Clicks. I believe we're extremely excited about what this campaign can achieve in further building emotion surrounding the ZYN brand and growing the brand franchise. I'd say the MRTP is nearly arriving as the icing on the cake. We felt sure it would arrive; we felt sure about the product's quality, but it's wonderful that we can now market the product with this reduced risk mention, and I've discussed that at length. This truly is a fantastic moment in the U.S. to speed things up. I'd say we're going to go 360; every lever available will be pulled to accelerate ZYN's growth and capitalize on this new situation. It will arrive, naturally, alongside substantial marketing and commercial activity at the point of sales. That's going to matter a great deal. I think you were asking, alright, what does that mean regarding promotional activity? You've noticed that Q2 saw less promotional activity; that explains why we're nearly flat year-over-year on revenue, with volume up slightly. I think we'll see. Naturally, I won't be making any forward-looking remarks about pricing moves — that kind of thing would run afoul of anti-competitive rules. There's a single premise that can't be touched: ZYN holds the top spot as the market's premium brand, and that position isn't going anywhere. All of our efforts on that front will aim at maximizing both volume expansion and earnings growth. Having stated that, there's nothing further I'm able to share on the matter; it simply shows the way we're approaching this. That's definitely true in the U.S., where after a number of disappointing quarters, this is a wonderful point in time, and it's excellent that we clearly have the ability to produce very robust growth even as we step up our spending in the U.S.

Bonnie Herzog

analyst
#12

All right. That was really useful. Maybe just one quick ZYN follow-up. I was hoping you could give us a bit more detail on how the ZYN Ultra launch is going, what early reactions you've gotten from retailers and consumers, what's happening with shelf space, and how much incremental volume you think it will bring? This morning you said there are plans to introduce the lower nicotine ZYN. I'd really like to hear how you plan to place it within the wider ZYN lineup and how incremental it might be. Thanks.

Emmanuel Babeau

executive
#13

Yes; regarding ZYN Ultra, I don't believe we should make too much of the initial 14 days. You've all watched those first 14 days of ZYN just as we have. It looks quite good. There's sequential growth. Our share is rising. Over that 14-day stretch, I think we're capturing a big portion of how the category is evolving. We've received quite a few favorable reactions from consumers. I'd say we should remain careful here, since we're discussing 14 days and much is still ahead, but the earliest figures and responses are definitely encouraging. Let's get a few more weeks in, and I'm confident that once summer is over, we'll understand far better what ZYN Ultra is delivering. As for your low nicotine question, I believe we've consistently stated — and this isn't unique to the U.S., but applies broadly across the nicotine pouch segment — that the 1.5 milligram strength strikes us as especially important for getting smokers to switch to this improved option. We're aware that an excessive level of nicotine can in fact produce an unpleasant experience and turn some of them away from adopting this product. Our hope is that this 1.5 milligram will assist literally millions of Americans who are genuinely trying out the category, so to speak, under the most advantageous circumstances and with the finest experience available. Naturally, I'll keep quiet about our rollout strategy and what actions we intend to take, since that information is sensitive. That essentially captures the thinking behind this 1.5 milligram.

Matt Smith

analyst
#14

Hello, and thanks for accepting my question, Emmanuel.

Emmanuel Babeau

executive
#15

Good morning, Matt.

Matt Smith

analyst
#16

Good morning. I'd like to explore a bit more deeply the Japan trends we saw this quarter, and even more crucially, how things are developing — from the perspective of category expansion in IMS and also how IQOS performed over the period. The total IQOS HTU share held up well, but could you provide additional color on the share movements inside IQOS, the split across the IQOS consumable lineup, and what you anticipate for the back half, especially since another excise tax hike lands in October — do you believe that will shift the phasing between the third and fourth quarters? Thanks.

Emmanuel Babeau

executive
#17

Yes, Matt. Of course. Glad to address that. Once more, perhaps I should begin by restating that the situation we've encountered in Japan matches what we anticipated; we understood it would be somewhat confusing to interpret given Q1 pantry loading, then Q2 with a negative effect initially followed by a rebound. Looking at Japan from a broad perspective, indeed, growth for the category has been decelerating. What alternative would you anticipate? For consumers in a nation where people aren't, shall we say, accustomed to seeing prices rise dramatically, this represents a major jump. A sort of cultural shock is taking place. Naturally, that creates disruption, yet it aligns with what we foresaw for the category. The result is that the category's growth has been losing momentum, though it continues to expand, and looking at the figures across Q2, we observe consistent improvement. Turning now to IQOS, we've clearly taken a bigger hit on TEREA, the priciest consumable brand. And SENTIA served as a quite effective cushion, so to speak, for the consumer. Without providing the exact figure, what we've observed is that SENTIA likely sits higher than its previous level while TEREA hasn't completely bounced back, owing to this shift from TEREA toward SENTIA. All told, we ended at 68%, having been at 69% during the prior quarter. Honestly, I can't even say whether that difference truly matters. We've been the one — as I mentioned again in my prepared comments — posting the largest hike with our JPY 40. The toughest part is now behind us, since that initial increase was the harshest. Regarding the pass-through, I won't reveal our H2 plans, but it's smaller; it's nearer to JPY 20 during the back half. We've endured the hardest stretch, and we recognize that for competitors to soak up their excise duty rise, they'd need to raise prices by more than we did, or else face serious negative fallout. That essentially sums up what we can share about Japan. This adjustment isn't entirely finished for us. As we've indicated, H2 will bring further disruption. My take is that we have strong confidence the toughest stretch is now behind us; the response came in exactly as we had anticipated, and I see that as evidence of how powerful IQOS is in that market; so now we move into H2, as I mentioned, with a smaller effect when it comes to pass-on; let me now address what lies ahead, since it matters to keep this in mind, and this element, in my view, will work in our favor. As you are aware, no combustible increase occurs in 2026; for 2027, a plan already exists — I believe it runs from 2027 through 2029, three years during which excise duty rises at a far more modest level, naturally, yet applied equally to CC and to heat-not-burn. Since we have shifted toward a fixed rate, that should unlock the door to what is likely a supportive situation in which, being the top brand on price, we take a proportionally lighter hit than the rest. This opens a chance to raise price, something that was rarely clear-cut before. The pass-on figure, as I see it, sits at roughly JPY 12 across the years to come. Likely following what was a hard period to digest in 2026, my sense is this will produce a far better picture in 2027 and afterward.

Matt Smith

analyst
#18

Matt, glad that was useful. Thanks, Emmanuel — I'll relay it.

Emmanuel Babeau

executive
#19

Thanks, Matt. Appreciate it.

Eric Serotta

analyst
#20

Morning, everyone. To start, Emmanuel, I appreciate everything — collaborating with you has truly been enjoyable. I'm eager to keep working alongside you going forward, Massimo. Wishing you the best, Emmanuel.

Emmanuel Babeau

executive
#21

Thanks. I really appreciate that, Eric. Many thanks.

Eric Serotta

analyst
#22

Eric, thanks. Back to Japan — can you give us some color on what competition looks like over there? Over the last 12 months, we clearly noticed more promotional push from a few of your rivals. As we start lapping the onset of that, what are you seeing, or how has it developed in the last few months? Obviously it's messy with the excise pass-through.

Emmanuel Babeau

executive
#23

Yeah, Eric. In Japan, as you'd expect, I'd say every player has all hands on deck, because the pass-on has come in two very strong steps. Folks are probably done tinkering with, let me attempt a promotion over here. Let me attempt some odd maneuver here and there. I think everyone is asking themselves, "How can I best absorb, to the fullest extent I'm able, what amounts to a large hike?" If your image in the market isn't the strongest, it becomes harder to persuade the consumer that your product is worth a meaningful price rise. My sense is everybody is somewhat in the thick of that. We've been pointing out, I think, that ahead of this excise duty alignment, or equalization, Japan Tobacco had been picking up share. I won't weigh in on the H1 trend, and I'm not even certain that right now it's simple to interpret what's happening. The fact that we're holding our share roughly steady — 68 against 69 — simply demonstrates that, yes, between competitor number two and competitor number three, there can be some shifting, yet ultimately we remain well in front of the field. I think we'll need things to settle somewhat as the year winds down to observe, with that additional price or excise duty hike I referenced, what the competitor's new approach turns out to be. As I see it, right now everyone is focused on truly working to absorb this substantial excise duty.

Eric Serotta

analyst
#24

That's really useful, thanks. I just want to ask one more quick thing about it. I noticed Japan Tobacco went to the Ministry of Finance regarding the October price hike. From what I can tell, it came in a touch under a complete pass-through of the excise. Does that line up with how you see it, given what's happening with pricing in the market? And have you folks submitted anything to the Ministry about October pricing yet?

Emmanuel Babeau

executive
#25

Well, I won't say anything about what a rival is up to. What the Ministry of Finance granted them is, I believe, public knowledge. Nor will I discuss their approach. As we've said before, speaking generally and not about any specific competitor, the excise duty equalization resulted in a price rise that was considerably larger for them than for us. Keep in mind that in our case, taken as a whole, it comes to roughly 10%. When it comes to the competitor, it might reach 20%. That's a far greater increase should they choose to pass it all along, though I have no idea what their plan is. As for us, regarding our own filing, since that's what you're asking about, it hasn't been made public yet, so I won't say anything about whether we've done something or not. If you can be patient with us just a bit, I'm confident you'll find out before long.

Faham Baig

analyst
#26

Hello, all. Thanks for letting me ask. I have a couple, if that works. First, just to clarify something, Emmanuel. You mentioned improving how ZYN is positioned on price premium. I realize ZYN Ultra has been launched, and that does support this, but does this also cover ZYN Flagship? I understand you're rightly mindful of share of market, but if so, might that additionally help speed up growth for the category, which right now sits near 20%? That's question one. Second, I realize pricing is a very delicate subject, and I'm not seeking any guidance about the future here. Would it be fair to think pricing will probably play a bigger role in how IQOS grows from here? Might that lever push gross margin at IQOS even higher?

Emmanuel Babeau

executive
#27

Certainly. Thanks for asking. Regarding optimizing, I'll return to my prior point: for us, optimizing means placing ZYN worldwide, and you'll permit me, naturally, not to go into detail on ZYN Dry, ZYN Ultra, or any future ZYN, but rather to set our ZYN variants at the price point where we get the most volume growth and bottom-line growth. Let me say it again. ZYN remains and will stay the market's premium leader, and naturally, this is a very thrilling market, the category expanding quickest within the U.S. We intend to capture our fair portion of that category's growth and do so profitably. That's our meaning when we talk about optimizing price, and I won't go further on it. Turning to IQOS. You've noticed it stands at 3%, all right, during this initial stretch of the year, the price rise for IQOS. To be clear, what matters most right now is optimizing volume, and I don't need to restate that IQOS consumables deliver twice the dollar per stick revenue, and even more for gross profit since gross margin is greater. Truly, optimizing volume is what matters most, though that doesn't stop us, naturally, tactically, whenever possible and without harming volume, from raising price. At present, that truly is the priority; over the long run, naturally, a point will arrive when IQOS grows larger. The market will eventually mature at some future moment, and at that moment, we are creating a brand that has no equal. I'm unsure whether people realize that our inclusion now in the Kantar list of the top 100 brands is quite an event. That's quite extraordinary. The brand is 10 years old. I believe we're building something very powerful regarding brand, and we all understand that a powerful brand later will mean our ability to raise price, since the consumer will perceive value in that brand. What we're doing is laying the groundwork so that, down the road, we have the ability to push pricing higher. As I mentioned, what comes first right now is getting the most out of our volumes.

Faham Baig

analyst
#28

Thanks, Emmanuel.

Emmanuel Babeau

executive
#29

Thank you.

Pallav Mittal

analyst
#30

Hello, everybody. I appreciate you answering my questions. There are 2 things I'd like to ask. To start, I have a question regarding IQOS in Europe. It's obvious that during the second quarter, a flavor ban in the markets that remained had an effect. You pointed out Poland, Hungary, and so on. Why are you confident that IQOS IMS will be able to speed up once more across Europe? Also, in your opinion, what would be a level that can be sustained, let's say, for the growth rate over the near term for IQOS in Europe? That was my first one.

Emmanuel Babeau

executive
#31

For that one, concerning Europe, I'll pass things to Massimo.

Massimo Andolina

executive
#32

Thanks. Appreciate the question. So, if you strip out what Poland and Hungary in particular have done to us this year — two markets affected by a characterizing flavor ban, and two markets where flavor propositions made up a high percentage of what we sold — the underlying growth trend in Europe really hasn't moved much. Where does my confidence come from? A few places. First, we've already been through this in a range of other markets. After the initial couple of quarters, when we obviously absorb a volume hit from the flavor ban, we go on to rebuild the same growth trajectory we had beforehand, which speaks to the commercial engine we've built and the strength of the portfolio. Second, we've been broadening the portfolio precisely to get ready for this. So today the portfolio is tiered vertically as well, thanks to the launch of DELIA. That's becoming increasingly important for us — for acquisition, and also in certain markets with significant tax increases, by giving consumers something more affordable. Even more significantly, many consumers, CC smokers especially, have found in DELIA an opportunity they grasp more easily and whose taste profile they feel fits their needs better. On top of that, you've seen us roll out LEVIA across a range of markets. That's our non-tobacco flavor proposition. Clearly it's still early days for it. It's a different kind of product, yet in many markets — Hungary definitely among them — we've quickly reached a double-digit percentage of our portfolio. Finally, I'd point out that our playground today isn't just IQOS. Over the past 24 months, you've seen us make a significant pivot to a multi-category commercial engine, where we also compete strongly with VEEV in the e-vape category. As Emmanuel mentioned earlier, within a couple of years we've gotten to the number one position in Europe in closed pods and disposables, and more recently, from a small base, in oral too, where the early signals in markets such as Poland, the U.K., or Austria are extremely encouraging. We've been outperforming the category on growth in those markets, so we're gaining share pretty much everywhere we've launched. Those are all the reasons we stay confident, even though the characterizing flavor ban is obviously a very disruptive action.

Pallav Mittal

analyst
#33

Alright, that clears things up nicely. I've got just one thing to ask about the guidance for group revenue across the whole year. I get that investments are higher, and that's the reason you aren't raising the EBIT outlook even after a solid H1. You mention improved cigarette volumes, plus stronger cigarette pricing alongside some unfavorable mix. Yet the group revenue guidance hasn't moved at all. Could you explain what's balancing that out when it comes to smoke-free volumes and pricing?

Emmanuel Babeau

executive
#34

Yes, absolutely. H1 delivered good growth for us, coming in at 5.3% on an organic basis, so things are dynamic even with Japan in the picture. Across the full year, our target sits at 5% to 7%. That leaves us plenty of room to stay inside the guidance while still having a highly dynamic H2. Our comfort in maintaining the guidance rests on that. As we've stated, we do anticipate stronger volume on CC. There's additional price, yet as we've noted, the mix works against us. That factor is probably offset to a large degree, as we've been explaining. That's the reason we feel fine holding the guidance steady, once more, drawing on H1 and the broader trajectory. On Smoke-Free, I'd also highlight that during H1, your shipment runs somewhat ahead of IMS, whereas across the full year, shipment and IMS should end up broadly in line; so we anticipate the opposite pattern. We anticipate IMS running slightly ahead of shipment during the latter half of the year, and that too will affect how our revenue grows. Like I said, when you examine the guidance alongside what we saw in H1, we're looking at another six months — H2, that is — of highly dynamic revenue growth, and we're aiming for operating income growth to accelerate. It isn't a case of us anticipating a slowdown in H2. In fact, it's quite the opposite.

Gerald Pascarelli

analyst
#35

Thanks a lot. I want to return to the combustible side. You beat expectations on volumes this quarter — can you share anything about whether that strength has carried into the early days of July? When I look at the comps, the volume comparisons for 3Q appear quite favorable, and honestly for the entire back half of the year too. I'm just wondering whether there's some conservatism baked into your volume guidance for the full year, or whether there are particular regional headwinds or timing items we should keep in mind while modeling. Thank you.

Emmanuel Babeau

executive
#36

No, there's nothing to call out. You'll forgive me for not beginning to discuss Q3 figures and July. What's driving the combustible strength in Q2 is countries that either lack a smoke-free product presence or have only a limited one. We're talking Turkey, India, Egypt. Indonesia has performed well too. These are markets, as we know, with large demographics. The legal-age cohorts keep expanding annually. There's a smoking trend. India, to me, is the perfect illustration. You're aware of how strong the demographics are there. Smoke-free products are prohibited, so combustible products capture the full benefit. That's the Q2 trend. Fine, that doesn't guarantee the remainder of the year will stay at that same level. Even so, this explains why we've revised the volume outlook somewhat, from roughly minus 3% to a decline of 2%-3%. That's what we can state at this point. Again, we observe a very large gap between nations where smoke-free products are widely accessible and those where they aren't.

James Bushnell

executive
#37

Appreciate it. That brings today's call to a close. Thanks for being with us. Should any follow-up questions come up, please reach out to the Investor Relations team. Thanks once more, and enjoy the rest of your day.

Emmanuel Babeau

executive
#38

Thank you all. Bye-bye. Bye.

Operator

operator
#39

This concludes today's conference call. Thank you for your participation. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Philip Morris International Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Philip Morris International Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Philip Morris International Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.